Cure8 trial brief
This trial tests several investigational long-acting antibody treatments (as monotherapies and combinations) for adults with moderate to severe ulcerative colitis using histologic and clinical remission endpoints — outcomes that matter to people aiming for deep disease control.
Adults with moderately to severely active ulcerative colitis, clinicians who treat UC, clinical researchers, and patients interested in experimental antibody therapies or platform trials.
This is a Phase 2, multicenter, proof-of-concept study run by Spyre Therapeutics. Part A (open-label) evaluated safety and preliminary efficacy of the individual investigational agents and completed enrollment in April 2026.
Part B is randomized, double-blind and placebo-controlled and began enrolling in April 2026 to compare the three monotherapies and three combination regimens against placebo.
The study’s primary outcomes include change in the Robarts Histopathology Index at Week 12 (Part A) and percentage of participants in clinical remission at Week 12 based on modified Mayo scores (Part B). Eligibility focuses on adults with moderately to severely active UC; people who have failed four or more advanced therapy classes are excluded.
This is a Phase 2, recruiting clinical trial record (ClinicalTrials.gov). The interventions are listed by study codes (SPY001–SPY003) with no marketed drug names or mechanisms provided in the record; the entry reports planned outcomes and eligibility but does not report trial results.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This trial tests palmitoylethanolamide (PEA), a commercially available supplement with anti-inflammatory actions, as an add-on treatment for mild-to-moderate ulcerative colitis.
This registry will provide real-world data on how etrasimod is used and performs in routine clinical practice in China, including patient characteristics, symptom trajectories, safety, and healthcare costs. Real-world...
A new antibody, duvakitug, showed higher remission/response rates than placebo in Phase 2b study data for both ulcerative colitis and Crohn’s disease, which could lead to a new treatment option if Phase 3 trials confirm...
